Novel antifolate drugs
- 1 April 2003
- journal article
- Published by Springer Science and Business Media LLC in Current Oncology Reports
- Vol. 5 (2), 114-125
- https://doi.org/10.1007/s11912-003-0098-3
Abstract
Antimetabolites are active chemotherapeutic agents for many solid tumor and hematologic malignancies. Folate antagonists, purine analogues, and pyrimidine analogues are the three main categories of antimetabolites. Methotrexate, the most studied folate antagonist, is effective in many malignancies. Methotrexate inhibits dihydrofolate reductase, which leads to accumulation of polyglutamated folates, causing further inhibition of thymidylate synthase and glycinamide ribonucleotide formyltransferase. Subsequently, the lack of reduced folate substrates impairs synthesis of purine nucleotides, thymidylate, and certain amino acids, which can lead to cell death. However, methotrexate resistance develops through several mechanisms, including decreased folate carrier-mediated membrane transport, dihydrofolate reductase gene amplification, specific transcription-translational modifications, and downregulation of intracellular methotrexate polyglutamation. Antifolate drug development has focused on agents designed to overcome different aspects of methotrexate resistance. This article reviews the enzymatic targets for antifolates, describes the known mechanisms of antifolate resistance, and summarizes the current development of novel antifolate agents. Discussed specifically are trimetrexate, edatrexate, raltitrexed, pemetrexed, ZD9331, lometrexol, LY309887, GW1843, OSI-7904(L), and nolatrexed, all of which have unique clinical pharmacology and are in various stages of development. The toxicity of antifolates has been sporadic and difficult to predict clinically. Supplementation with folic acid and vitamin B12 has been shown to reduce the toxicity of pemetrexed without affecting efficacy and has increased the therapeutic index for this novel agent.Keywords
This publication has 60 references indexed in Scilit:
- Role of surgery in the treatment of bilio-pancreatic cancer: The European experienceSeminars in Oncology, 2002
- Pharmacogenetics and Folate Metabolism –a Promising DirectionPharmacogenomics, 2002
- Phase I trials of pemetrexedSeminars in Oncology, 2002
- Folate-binding triggers the activation of folylpolyglutamate synthetase 1 1Edited by I. WilsonJournal of Molecular Biology, 2001
- Human 5-Aminoimidazole-4-carboxamide Ribonucleotide Transformylase/Inosine 5′-Monophosphate CyclohydrolaseJournal of Biological Chemistry, 2001
- A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancerBritish Journal of Clinical Pharmacology, 1999
- Mechanisms of Methotrexate Resistance in Acute LeukemiaPublished by Springer Science and Business Media LLC ,1999
- Methotrexate Transport and ResistanceLeukemia & Lymphoma, 1998
- The Human Glycinamide Ribonucleotide Transformylase Domain: Purification, Characterization, and Kinetic MechanismArchives of Biochemistry and Biophysics, 1997
- Methotrexate Pharmacology and Resistance in Childhood Acute Lymphoblastic LeukemiaLeukemia & Lymphoma, 1996